Prodrug strategies in nasal drug delivery

Bibliography

• BEHL CR, PIMPLASKAR HK, SILENO, DEMILERES J, ROMEO VD: Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Del. Rev (1998) 29:89–116.
   PubMed Web of Science ®Google Scholar
• •Detailed review of nasal formulations.
   Google Scholar
• TIRUCHERAI GS, YANG C, MITRA AK: Prodrugs in nasal drug delivery. Expert Opin. Biol. Ther. (2000) 1(1):49–66.
   Google Scholar
• PONTIROLI AE: Peptide hormones: review of current and emerging uses by nasal delivery. Adv. Drug Del. Rev (1998) 29:81–87.
   PubMed Web of Science ®Google Scholar
• TIRUCHERAI GS, PEZRON I, MITRA AK: Novel approaches to nasal delivery of peptides and proteins. STP Phanna Sci. (2002)12:3–12.
   Google Scholar
• LEE VH, YAMAMOTO A, KOMPELLA UB: Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev Ther. Drug Carr. Syst. (1991) 8:91–192.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of penetration enhancers.
   Google Scholar
• HUSSAIN AA, HIRAI S, BAWARSI R: absorption of propanolol in rats. J. Phann. Sci. (1979) 68:1196–1199.
   PubMed Web of Science ®Google Scholar
• •Early work showing similar bioavailability between the iv. and intranasal routes.
   Google Scholar
• HUSSAIN AA: Intranasal drug delivery. Adv. Drug Del. Rev. (1998) 29:39–49.
   PubMed Web of Science ®Google Scholar
• HIRAI S, YASHIKI T, MATSUZAWA T, MIMA H: Absorption of drugs from the mucosa. Int. J. Phann. (1981) 7:317–325.
   Web of Science ®Google Scholar
• •Analysis of the mechanisms of nasal absorption.
   Google Scholar
• TIRUCHERAI GS, PEZRON I, MITRA AK: Novel approaches to nasal delivery of peptides and proteins. STP Phanna Sci. (2002) 12:3–12
   Google Scholar
• HIRAI S, YASHKI T, MIMA H: Effect of surfactants on the nasal absorption of insulin in rats. Int. J. Phann (1981) 9:165–172.
   Web of Science ®Google Scholar
• •Detailed analysis of surfactant effects on nasal absorption.
   Google Scholar
• MITRA R, PEZRON I, CHU WA, MITRA AK: Lipid emulsions as vehicles for enhanced nasal delivery of insulin. Int. J. Phann. (2000) 205:127–134.
   PubMed Web of Science ®Google Scholar
• VADOLAS J, WIJBURG OLC, STRUGNELL RA: Liposomes as systemic and mucosal delivery vehicles. Drug Targeting Delivery (1997) 8:73–100.
   Google Scholar
• ILLUM L, JORGENSEN H, BIGSGAARD H, KROGSGAARD 0, ROSSING N: Bioadhesive microspheres as nasal drug delivery system. Int. J. Phann. (1987) 39:189–199.
   Web of Science ®Google Scholar
• •Introduction of bioadhesive microspheres to prolong drug residence time in the nasal cavity.
   Google Scholar
• BETBEDER D, SPERIANDO S, LATAPIE et al: Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. Phann. Res. (2000) 17:743–748.
   PubMed Web of Science ®Google Scholar
• •New technology.
   Google Scholar
• SANKAR C, RANI M, SRIVASTAVA AK, MISHRA B: Chitosan based pentazocine microspheres for intranasal systemic delivery: development and evaluation. Phannazie (2001) 56:223–226.
   Google Scholar
• WORTH LL, JIA SF, ZHOU Z, CHEN L, KLEINERMAN ES: Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res. (2000) 6:3713–3718.
   PubMed Web of Science ®Google Scholar
• SHINGAKI T, SAKANE T, YAMASHITA S et al.: Transnasal delivery of anticancer drugs to the brain tumor: a new strategy for brain tumor chemotherapy. Drug Del. Syst. (1999) 14:365–371.
   Google Scholar
• ADJEI A, SUNDBERG D, MILLER J, CHUN A: Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Phann. Res. (1992) 9:244–249.
   PubMed Web of Science ®Google Scholar
• DAVIS SS: Nasal vaccines. Adv. Drug Del. Rev (2001) 51:21–42.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review.
   Google Scholar
• ILLUM L, JABBAL-GILL I, M, FISHER AN, DAVIS SS: Chitosan as a novel delivery system for vaccines. Adv. Drug Del. Rev (2001) 51:81–96.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of chitosan formulations.
   Google Scholar
• KRISHNAMOORTHY R, MITRA AK: Prodrugs for nasal drug delivery. Adv. Drug Del. Rev (1998) 29:135–146.
   PubMed Web of Science ®Google Scholar
• STELLA VJ, CHARMAN WNA, NARINGGREKAR VH: Prodrugs: do they have advantages in clinical practice? Drugs (1995) 29:455–473.
   Google Scholar
• GIBSON D, RICHARD E, OLANOFF LS:Physicochemical determinants of nasal drug Cont. Rd (1987) 6:361–366.
   Google Scholar
• DUCHATEAU JS, ZUIDEMA J, ALBERS WM, MERKUS FW: Nasal absorption of alprenolol and metaprolol. Int. I Pharm. (1986) 34:131–136.
   Google Scholar
• CORBO DC, HUANG YC, CHIEN YW: Nasal delivery of progestational steroids in ovariectomized rabbits II: Effect of penetrant hydrophilicity. hat. Pharm. (1989) 50:253–260.
   Google Scholar
• SHAO Z, PARK JB, R, MITRA AK: Physicochemical properties, plasma enzymatic hydrolysis and nasal absorption of acyclovir and its 2'-ester prodrugs. Pharm. Res. (1994) 11:237–242.
   PubMed Web of Science ®Google Scholar
• SHAO Z, HOFFMAN AJ, MITRA AK: Biodegradation characteristics of acyclovir 2'-esters by respiratory carboxylesterases: implications in prodrug design for intranasal and pulmonary delivery. hat. .1. Pharm. (1994) 112:181–190.
   Google Scholar
• •Effect of prodrug side chain branching on mucosal hydrolysis.
   Google Scholar
• SAYANI AP, CHIEN YW: Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev Titer. Drug Carr. Syst. (1996) 13:85–184.
   PubMed Web of Science ®Google Scholar
• MOESS J, BUNDGAARD H: Prodrugs of peptides: bioreversible derivatization of thyrotropin-releasing hormone (TRH) by N-phthalidylation of its imidazole moiety. Int. Pharm. (1991) 74:67–75.
   Web of Science ®Google Scholar
• BUNDGAARD H: The utility of prodrug approach to improve peptide absorption. Cont. Rd (1992) 21:63–72.
   Google Scholar
• •Detailed prodrug strategies.
   Google Scholar
• BARLOW D, TAKASHI S: The design of peptide analogues for improved absorption. Cont. Rd (1994) 29:283–291.
   Web of Science ®Google Scholar
• •Systematic prodrug design.
   Google Scholar
• KIYA K, UOZUMI T, OGASAWARA H et al.: Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother. Pharmacol (1992) 29:339–342.
   PubMed Web of Science ®Google Scholar
• SHINKEL AH, WAGENAAR E, MOLS CAAM, VAN DEEMTER L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Clin. Invest. (1996) 97:2517–2524.
   Google Scholar
• YANG C, TIRUCHERAI GS, MITRA AK: Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther. (2001) 1:1–17.
   Google Scholar
• •Review containing numerous examples of-mediated prodrug delivery.
   Google Scholar
• YANG CY, DANTZIG AH, PIDGEON: Intestinal peptide transport systems and oral drug bioavailability. Pharm. Res. (1999) 16:1331–1343.
   PubMed Web of Science ®Google Scholar
• DEVRUEH RL, SMITH PL, LEE CP: Transport of L-valine acyclovir via the oligopeptide transporter in the human intestinal cell line Caco-2. Phannacol Exp. Ther. (1998) 286:1166–1170.
   PubMedGoogle Scholar
• GALIETTA LJV, MUSANTE L, ROMIO et al: An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells. Am. J. Physiol (1998) 275:L917–L923.
   Google Scholar
• TENGAMNUAY P. MITRA AK: Transport of tyrosine and phenylalanine across the rat nasal mucosa. Life Sci. (1988) 43:585–593.
   PubMed Web of Science ®Google Scholar
• AGU RU, DANG HV, JORISSEN Met al.: Do large neutral amino acid transporters exist in human nasal epithelium? AAPS PharmSci. (2001) 3(3):526.
   Google Scholar
• YANG C, MITRA AK: Nasal absorption of tyrosine-linked model compounds. Pharm. Sci. (2001) 90:340–347.
   PubMed Web of Science ®Google Scholar
• •First report to document carrier-mediated approach for nasal drug delivery.
   Google Scholar
• YANG C, GAO H, MITRA AK: Chemical stability, enzymatic hydrolysis and nasal uptake of amino acid ester prodrugs of acyclovir.j Flamm. ScL (2001) 90:617–624.
   Google Scholar
• SAKANE T, AKIZUKI M, YOSHIDA M et al.: Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J. Phann. Phannacol (1991) 43:449–451.
   PubMed Web of Science ®Google Scholar
• SIRGUDSSON P, THORVALDSSON T, GIZURARSON S: Olfactory absorption of insulin to the brain. Drug Del. (1997) 4:195–200.
   Google Scholar
• MATHISON S, NAGILLA R, KOMPELLA UB: Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? Drug Del. (1998) 5:415–441.
   Google Scholar
• KRISTENSSON K, OLSSON Y: Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol (1971) 19:145–154.
   PubMed Web of Science ®Google Scholar
• SAKANE T, AKIZUKI M, YAMASHITA S et al.: The transport of drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (1991) 39:2456–2458.
   PubMed Web of Science ®Google Scholar
• CHOU KJ, DONOVAN MD: of antihistamines into the CSF following intranasal delivery. Biopharm. Dispos. (1997) 18:335–346.
   PubMed Web of Science ®Google Scholar
• CHOU KJ, DONOVAN MD: The distribution of local anesthetics into the CSF following intranasal administration. Int. J. Pharm. (1998) 168:137–145.
   Web of Science ®Google Scholar
• CHEN XQ, FAWCETT JR, RAHMAN YE, ALA TA, FREY WH: Delivery of nerve growth factor to the brain via the olfactory pathway. AlzheimerS Dis. (1998) 1:35–44.
   PubMedGoogle Scholar
• ILLUM L: Transport of drugs from the nasal cavity to the central nervous system. Eur. Pharm. Sci. (2000) 11:1–18.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive treatise on nose to braindrug delivery.
   Google Scholar
• KAO HD, TRABOULSI A, ITOH S, DITTERT L, HUSSAIN A: Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm. Res. (2000) 17:978–984.
   PubMed Web of Science ®Google Scholar
• ••A novel method for the treatment ofParkinson's disease.
   Google Scholar
• WIOLAND MA, FLEURY-FEITH J, CORLIEU P et al: CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. Histochem. Cytochem. (2000) 48:1215–1222.
   PubMed Web of Science ®Google Scholar
• HENRIKSSON G, NORLANDER T, ZHENG X, STIERNA P, WESTRIN KM: Expression of P-glycoprotein 170 in nasal mucosa may be increased with topical steroids. Am.! Rhino] (1997) 11:317–321.
   PubMedGoogle Scholar